Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #35 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Alembic Pharmaceuticals Limited (this stock) | 16,339 | 22.3 | 11.8% | -8.3% | 1.44% | 74 | 57 | 82 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 2,150 | 221 | 172 | ₹ |
| March 31, 2026 | 1,848 | 118 | 202 | ₹ |
| Dec. 31, 2025 | 1,876 | 163 | 132 | ₹ |
| Sept. 30, 2025 | 1,910 | 222 | 184 | ₹ |
| June 30, 2025 | 1,711 | 191 | 154 | ₹ |
| March 31, 2025 | 1,770 | 193 | 157 | ₹ |
| Dec. 31, 2024 | 1,693 | 177 | 138 | ₹ |
| Sept. 30, 2024 | 1,648 | 180 | 153 | ₹ |
| June 30, 2024 | 1,562 | 157 | 135 | ₹ |
| March 31, 2024 | 1,517 | 183 | 178 | ₹ |
| Dec. 31, 2023 | 1,631 | 185 | 180 | ₹ |
| Sept. 30, 2023 | 1,595 | 135 | 137 | ₹ |
| June 30, 2023 | 1,486 | 130 | 121 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 7,345 | 694 | 671 |
| March 31, 2025 | 6,672 | 706 | 582 |
| March 31, 2024 | 6,229 | 633 | 616 |
| March 31, 2023 | 5,653 | 386 | 342 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 783 | -506 | -164 | 435 | 348 |
| March 31, 2025 | 88 | -568 | 444 | 564 | -476 |
| March 31, 2024 | 803 | -321 | -438 | 327 | 476 |
| March 31, 2023 | 724 | -448 | -262 | 443 | 281 |
| March 31, 2022 | 552 | -372 | -217 | 426 | 127 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 8,763 | 5,669 | 5,636 | 1,239 | 122 | 4,543 | 2,594 | 196 | 2,844 | 2,511 |
| March 31, 2025 | 7,773 | 5,190 | 5,152 | 1,196 | 0 | 4,088 | 2,412 | 83 | 2,524 | 2,288 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
